Alpha-1-proteinase inhibitor
- Generic Name
- Alpha-1-proteinase inhibitor
- Brand Names
- Aralast, Glassia, Prolastin, Prolastin-C, Respreeza, Zemaira
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9041-92-3
- Unique Ingredient Identifier
- F43I396OIS
- Background
Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.
- Indication
For chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
- Associated Conditions
- Emphysema
- Associated Therapies
- Augmentation, Maintenance therapy
Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
- Conditions
- Interventions
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2019-04-12
- Lead Sponsor
- Stanford University
- Registration Number
- NCT02087813
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction
- First Posted Date
- 2013-09-06
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 10
- Registration Number
- NCT01936896
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 72
- Registration Number
- NCT00486837
The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency
- Conditions
- Interventions
- First Posted Date
- 2006-03-10
- Last Posted Date
- 2014-08-19
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 38
- Registration Number
- NCT00301366
- Locations
- 🇺🇸
University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇬🇧University of Cambridge - Cambridge Institute for Medical Research, Cambridge, England, United Kingdom
Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient Adults
- Conditions
- Interventions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 24
- Registration Number
- NCT00295061
- Locations
- 🇺🇸
National Jewish Medical and Research Center, Denver, Colorado, United States
🇺🇸St Lukes-Roosevelt Hospital Center, New York, New York, New York, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)
- Conditions
- Interventions
- First Posted Date
- 2005-12-09
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Grifols Therapeutics LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00263887
- Locations
- 🇩🇰
Gentofte Hospital Department of Respiratory Medicine, Hellerup, Denmark
🇸🇪Department of Pulmonary Medicine, Malmö University Hospital, Malmö, Sweden
🇬🇧Queen Elizabeth Hospital, Birmingham, England, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.